Development of experimental treatments for patients with retinitis pigmentosa
Copyright © 2023 The Author(s). Published by Elsevier España, S.L.U. All rights reserved..
Retinitis pigmentosa (RP) is a group of inherited diseases that lead to degeneration of the retina and decreased vision. The World Health Organization reports around 1,300 million people affected by some type of visual impairment worldwide. The prevalence is 1 in every 4000 inhabitants and it is the first cause of blindness of genetic origin, frequent in men with a percentage of 60% and 40% in women. There is a lack of information on this pathology in the world, mainly on the existing treatments for this disease, so this bibliographic review aims to update the existing or under-study treatments and inform the limitations of each of these therapies. This review of scientific literature was carried out by consulting databases such as PubMed and Web of science, the search will be limited to articles from the years 2018-2022. There are several types of therapy in studies: gene therapy, transcorneal electrical stimulation, use of neuroprotectors, optogenic therapy, stem cell transplants and oligonucleotide therapy, which will be discussed in this article, both their benefits and the existing barriers in each treatment experimental. In conclusion, each of these therapies promises a viable treatment in the future for selective groups of people with retinitis pigmentosa, however, some therapies have shown benefit at the beginning of the disease, losing their efficacy in the long term.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
Archivos de la Sociedad Espanola de Oftalmologia - 98(2023), 11 vom: 15. Nov., Seite 646-655 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lozano B, L L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blindness |
|---|
| Anmerkungen: |
Date Completed 06.11.2023 Date Revised 06.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oftale.2023.08.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361382405 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361382405 | ||
| 003 | DE-627 | ||
| 005 | 20231226085023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oftale.2023.08.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361382405 | ||
| 035 | |a (NLM)37640142 | ||
| 035 | |a (PII)S2173-5794(23)00141-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lozano B, L L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of experimental treatments for patients with retinitis pigmentosa |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.11.2023 | ||
| 500 | |a Date Revised 06.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Retinitis pigmentosa (RP) is a group of inherited diseases that lead to degeneration of the retina and decreased vision. The World Health Organization reports around 1,300 million people affected by some type of visual impairment worldwide. The prevalence is 1 in every 4000 inhabitants and it is the first cause of blindness of genetic origin, frequent in men with a percentage of 60% and 40% in women. There is a lack of information on this pathology in the world, mainly on the existing treatments for this disease, so this bibliographic review aims to update the existing or under-study treatments and inform the limitations of each of these therapies. This review of scientific literature was carried out by consulting databases such as PubMed and Web of science, the search will be limited to articles from the years 2018-2022. There are several types of therapy in studies: gene therapy, transcorneal electrical stimulation, use of neuroprotectors, optogenic therapy, stem cell transplants and oligonucleotide therapy, which will be discussed in this article, both their benefits and the existing barriers in each treatment experimental. In conclusion, each of these therapies promises a viable treatment in the future for selective groups of people with retinitis pigmentosa, however, some therapies have shown benefit at the beginning of the disease, losing their efficacy in the long term | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Blindness | |
| 650 | 4 | |a Ceguera | |
| 650 | 4 | |a Experimental treatments | |
| 650 | 4 | |a Fotorreceptores | |
| 650 | 4 | |a Genetic background | |
| 650 | 4 | |a Origen genético | |
| 650 | 4 | |a Photoreceptors | |
| 650 | 4 | |a Retinitis pigmentosa | |
| 650 | 4 | |a Retinosis pigmentaria | |
| 650 | 4 | |a Tratamientos experimentales | |
| 700 | 1 | |a Cervantes A, L A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archivos de la Sociedad Espanola de Oftalmologia |d 2018 |g 98(2023), 11 vom: 15. Nov., Seite 646-655 |w (DE-627)NLM27191520X |x 2173-5794 |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2023 |g number:11 |g day:15 |g month:11 |g pages:646-655 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oftale.2023.08.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 98 |j 2023 |e 11 |b 15 |c 11 |h 646-655 | ||